Catalog No.: PC-38343Not For Human Use, Lab Use Only.
Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations, shows potential against T790M-mediated drug resistance.
Rezivertinib (BPI-7711) is a novel third-generation EGFR tyrosine kinase inhibitor selective for EGFR-sensitizing and T790M mutations, shows potential against T790M-mediated drug resistance.
Rezivertinib (BPI-7711) specifically and covalently binds to and inhibits selective EGFR mutations, with particularly high selectivity against the T790M mutation, prevents EGFR mutant-mediated signaling and leads to cell death in EGFR mutant-expressing tumor cells.
Rezivertinib (BPI-7711) shows minimal activity against wild-type EGFR (wt EGFR), and does not cause dose-limiting toxicities that occur during the use of non-selective EGFR inhibitors, which also inhibit wt EGFR.
